Literature DB >> 21812739

Genetic variants in the RAB7L1 and SLC41A1 genes of the PARK16 locus in Chinese Parkinson's disease patients.

Yaping Yan1, Jun Tian, Xiaoyun Mo, Guohua Zhao, Xinzhen Yin, Jiali Pu, Baorong Zhang.   

Abstract

We performed direct DNA sequencing of the RAB7L1 and SLC41A1 genes within the PARK16 locus in 205 Chinese Parkinson's disease (PD) patients. Three novel heterozygous variants were identified in SLC41A1: c.436A > G (causing p.Lys146Glu), c.1440A > G (causing p.Pro480Pro), and c.552 + 50G > A. These three variants were not present in any of the 210 genetically unrelated healthy controls of the same ethnic origin. No changes were identified in the RAB7L1 gene. Additionally, for the eight core PARK16 SNPs, no significant difference in allele or genotype frequencies was observed between PD patients and controls. Further analysis is required to determine the role of genes within the PARK16 locus in development of PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812739     DOI: 10.3109/00207454.2011.598983

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  10 in total

1.  SLC41A1 and TRPM7 in magnesium homeostasis and genetic risk for Parkinson's disease.

Authors:  Morgan Sturgeon; Perry Wu; Robert Cornell
Journal:  J Neurol Neuromedicine       Date:  2016-12-30

2.  Fine mapping and resequencing of the PARK16 locus in Parkinson's disease.

Authors:  Lasse Pihlstrøm; Aina Rengmark; Kari Anne Bjørnarå; Nil Dizdar; Camilla Fardell; Lars Forsgren; Björn Holmberg; Jan Petter Larsen; Jan Linder; Hans Nissbrandt; Ole-Bjørn Tysnes; Espen Dietrichs; Mathias Toft
Journal:  J Hum Genet       Date:  2015-04-09       Impact factor: 3.172

3.  Genetic Analysis of the ZNF512B, SLC41A1, and ALDH2 Polymorphisms in Parkinson's Disease in the Iranian Population.

Authors:  Faranak Madadi; Mahmoud Shekari Khaniani; Ehsan Esmaili Shandiz; Hormoz Ayromlou; Safa Najmi; Babak Emamalizadeh; Shaghayegh Taghavi; Javad Jamshidi; Abbas Tafakhori; Gholam-Ali Shahidi; Hossein Darvish
Journal:  Genet Test Mol Biomarkers       Date:  2016-09-09

Review 4.  The SLC41 family of MgtE-like magnesium transporters.

Authors:  Jaya Sahni; Andrew M Scharenberg
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

5.  Solute Carrier Family SLC41, what do we really know about it?

Authors:  Andrea Fleig; Monika Schweigel-Röntgen; Martin Kolisek
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2013

6.  Substitution p.A350V in Na⁺/Mg²⁺ exchanger SLC41A1, potentially associated with Parkinson's disease, is a gain-of-function mutation.

Authors:  Martin Kolisek; Gerhard Sponder; Lucia Mastrototaro; Alina Smorodchenko; Pierre Launay; Juergen Vormann; Monika Schweigel-Röntgen
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

7.  Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis.

Authors:  Jing Xie; Chien-Shan Cheng; Xiao Yan Zhu; Ye Hua Shen; Li Bin Song; Hao Chen; Zhen Chen; Lu Ming Liu; Zhi Qiang Meng
Journal:  Aging (Albany NY)       Date:  2019-05-08       Impact factor: 5.682

8.  Identification of SLC41A3 as a novel player in magnesium homeostasis.

Authors:  Jeroen H F de Baaij; Francisco J Arjona; Michiel van den Brand; Marla Lavrijsen; Anke L L Lameris; René J M Bindels; Joost G J Hoenderop
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

9.  Distinctive roles of Rac1 and Rab29 in LRRK2 mediated membrane trafficking and neurite outgrowth.

Authors:  Min Feng; Xin Hu; Na Li; Fan Hu; Fei Chang; Hong-Fei Xu; Yong-Jian Liu
Journal:  J Biomed Res       Date:  2018-03-26

10.  SNPs rs11240569, rs708727, and rs823156 in SLC41A1 Do Not Discriminate Between Slovak Patients with Idiopathic Parkinson's Disease and Healthy Controls: Statistics and Machine-Learning Evidence.

Authors:  Michal Cibulka; Maria Brodnanova; Marian Grendar; Milan Grofik; Egon Kurca; Ivana Pilchova; Oto Osina; Zuzana Tatarkova; Dusan Dobrota; Martin Kolisek
Journal:  Int J Mol Sci       Date:  2019-09-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.